We isolated and characterized crp* mutations in Escherichia coli that allow cyclic AMP (cAMP) receptor protein to function without cAMP. These mutants defined a region involved in the cAMP-induced allosteric change of cAMP receptor protein that is necessary for activation of the protein. Currently, we have isolated intragenic suppressors of the crp* mutations. These crp*(Sup) mutants require cAMP for activity. The c,p*(Sup) mutations map in regions which define new sites of changes involved in cAMP receptor protein activation. From these results, we suggest that to activate cAMP receptor protein cAMP brings about (i) a hinge reorientation to eject the DNA-binding F a-helices, (ii) proper alignment between the two subunits, and (iii) an adjustment between the position of the two domains. Cyclic GMP fails to effect the last step.
The cyclic AMP (cAMP) receptor protein (CRP) of Escherichia coli is a DNA-binding protein that functions to activate or repress transcription of many operons, depending upon the specific binding site for CRP and its location in the operon (for reviews see references 1, 8, 15, 24, and 30) .
The structure and function of CRP have been studied genetically, biochemically, and by physical means. The protein only shows nonspecific binding to DNA and is inactive for site-specific DNA binding. When cAMP is bound the protein changes conformation, as shown by fluorescence and X-ray scattering studies (21, 32, 33) and also by changes in protease sensitivity (12, 20) . In this cAMP-induced conformation, the protein binds with higher affinity to specific sites on DNA.
The structure of CRP in complex with cAMP is known from X-ray crystallographic studies at a resolution of 0.25 nm (22, 31a) . The structure of CRP in the absence of cAMP is not known, however, because of difficulty in obtaining crystals unless cAMP is present. Were the structure without cAMP known, it might be possible to predict the various alterations that the structure goes through to become activated. We are taking a genetic approach to identifying these cAMP-induced structural changes. We are investigating the individual sites of the cAMP-induced conformational change of CRP by analyzing mutant CRPs. We have isolated different classes of mutants: those that act independently of cAMP, called crp*, and derivatives of crp* which have regained cAMP dependence, called crp*(Sup).
CRP is a dimer, even in the absence of cAMP, consisting of identical subunits of Mr 22,500 (6, 28) . Each subunit can be divided into two domains. (i) The larger, amino-terminal domain is responsible for the subunit-subunit contacts to form the dimer. This domain also binds cAMP in a pocket formed by a series of antiparallel ,-sheets. (ii) The smaller, carboxy-terminal domain is responsible for DNA binding with specific contacts in the F a-helix. The two domains are connected covalently by a hinge region (3, 10, 12, 22; (4, 5, 7, 14, 16, 17, 23, 25, 29) . The nucleotide sequence for some of these mutations has been determined (4, 14, 17).
These mutations have been found to cause substitution in a number of places in the protein. We found some of these mutations allowing cAMP independence (CRP* phenotype) to be located in the D a-helix of the carboxy domain near the hinge region of the protein, connecting the two domains (14) ( Fig. 2) . One of these mutations caused substitution of a serine for a glycine at amino acid position 141. In the wild-type protein, glycine-141 in the D a-helix of the carboxy-terminal domain is on a side that would be facing the C a-helix of the amino-terminal domain, across the hinge (Fig.  2 ). Since substitution of serine for glycine at that position would add an amino acid side group that was longer and more polar, we proposed that the relationship of the D a-helix to the C a-helix is altered, either in orientation or in distance, between the two a-helices. Another single mutation in the D a-helix which gave a CRP* phenotype caused substitution at amino acid position 144 (14) . In this case, substitution of threonine for alanine allows the protein to be cAMP independent. Amino acid 144 in the D a-helix, based on the structure, faces away from the C a-helix toward the DNA-binding F a-helix of the carboxy-terminal portion of the protein (Fig. 2) . In this case also the mutant amino acid has a larger side group than does the wild type. We proposed that the larger side group of the threonine in the mutant pushes the F a-helix away from the D a-helix, facilitating the movement of the F a-helix away from the main body of the protein and enabling it to enter the major grooves of the DNA (14) . In our model, the crp*-141 and crp*-144 mutant proteins in the absence of cAMP are approximating the conformation that the wild-type protein assumes only in the presence of cAMP. Indeed, purified CRPs from two such mutants have been analyzed biochemically and shown in the absence of cAMP to exhibit a structure similar to that of wild-type CRP in the presence of cAMP (17; Y. L. Ren, S. Garges, S. Adhya, and J. S. Krakow, Proc. Natl. Acad. Sci. USA, in press). Therefore, the changes in these mutants indicate places within the protein where cAMP induces conformational changes.
The concept of genetic suppression has been applied to many different cases to define contacts and relationships between and within proteins (18, 19) . Recently, Shortle and Lin (27) used intragenic suppression to analyze the structure of Staphylococcus nucleus. By site-specific mutagenesis, we changed amino acids that we believe would interact with amino acids where CRP* changes are located, and we demonstrated suppression of the cAMP-independent phenotype (J. Kim, S. Garges, and S. Adhya, manuscript in preparation). For this report, we used intragenic suppression to identify new regions within CRP that are potentially related to the previously defined CRP* sites and are involved in the cAMP-induced allosteric change. We isolated and studied intragenic suppressors of crp*-141 and crp*-144 mutations, and we designate such mutants as crp*(Sup).
MATERIALS AND METHODS
The crp gene was cloned in the phage lambda vector D69 into the BamHI site of the phage int gene (14) . Mutagenesis of k crp* phages was carried out by growth on a mutD mutator strain (9), obtained from Lynn Enquist. Crp*(Sup) phages were selected on strain G806 (F-his relA rpsL Acya-854 Acrp-bs990) and screened on strains G698 (F-his relA rpsL Acya-854) and G806, with or without cyclic nucleotide at 2.5 mM. Media, lactose utilization determinations, and ,B-galactosidase activity measurements have been described previously (14) . Strain SA500 is F-his relA rpsL (2) .
Plasmids carrying the crp*(Sup) genes were constructed by endonuclease BamHI digestion of the crp*(Sup) phage DNA and ligation into pBR322. The nucleotide sequence of the crp*(Sup) genes was determined with double-stranded DNA as described previously (14) .
Strains containing the crp*(Sup) gene in single copy were made by lysogenizing G806 with the A crp*(Sup) phage at the attX site with a A imm-21 int+ helper phage.
RESULTS
Isolation and classification of crp mutations: crp*(Sup). To obtain intragenic suppressors of the previously described cAMP-independent crp (crp*) mutations, the X crp* phages were grown on a host strain containing the mutator allele mutD (9) . Based on the number of clear plaque mutants of A (X c) obtained after mutagenesis, the mutation frequency was calculated to be approximately 0.1%.
The k crp* phages produce red Lac' plaques on MacConkey lactose indicator plates in strains which lack cAMP (cya) because the mutant CRP can function in vivo without cAMP (14) . After mutagenesis of these phages, we chose phages which produced white turbid Lac-plaques. These phages would potentially be of three types: (i) those acquiring a new crp null mutation, (ii) true wild-type (crp+) FIG. 2. Interactions between amino acids in the hinge region of CRP. At the bottom, a CRP monomer is represented bound to DNA. At the top is shown in expanded form the hinge region that connects the large and small domains and the DNA-binding F a-helix. Lines:
(-.--) van der Waals radii for wild-type amino acids, (---) van der Waals radii for substituted amino acids that cause a CRP* or cAMP-independent phenotype. revertants of crp*, and (iii) mutants that contained the crp* mutation but had another mutation to suppress the CRP* phenotype. The three classes of phages are described in Table 1 . Among the white plaque-producing phages, class 1 mutants, those which had a new crp mutation that produced an inactive CRP, were screened out because they could not complement a crp cya strain in the presence of cAMP on MacConkey lactose plates. The other two classes, 2 and 3, could, because they produced a functional CRP. To distinguish the true revertants (class 2) from the phages containing the crp* mutation as well as the suppressor mutations (class 3), marker rescue experiments were performed. For this, the candidate mutant phage lysates were spotted onto a lawn of a Acya crp+ strain (G698) on MacConkey lactose plates. Unlike the parental crp* phages, the true revertants and the crp* suppressor mutant phages make white plaques on this strain. After 2 days of incubation at 32°C, however, some plaques gave rise to red (Lac') papillae. The phage which produced no red papillae were thought to be true revertants; phages which are phenotypically similar but produce red papillae must still contain the crp* mutation since it could be rescued from the phage. The red papillae were due to the crp* mutation, producing CRP which could function without cAMP. Phages containing the crp* mutation as well as the suppressor mutation are called A crp*(Sup).
Mutational changes in the crp*(Sup) genes. One suppressor mutant for each of two crp* mutations, crp*-141 and crp*-144, was chosen for further study. The crp*(Sup) mutations on the phage were crossed into a pBR322 plasmid by cloning the entire crp gene and flanking regions. The DNA sequence changes in these crp*(Sup) mutants were determined as described previously (14) by using double-stranded plasmid DNA.
The sequence changes are shown in Figure 3 . The crp*-141 mutation was suppressed by a transition mutation (ACT -* GCT) changing amino acid 127 from a threonine to an alanine. The crp*-144 mutant was suppressed by two closely linked transition mutations changing amino acids at positions 169 and 171 from arginine and glutamic acid to cysteine (CGT --TGT) and glycine (GAA -* GGA).
Comparison of physiological characteristics of crp* and crp*(Sup) strains. To characterize the mutants, a strain deleted for both the crp and cya genes (G806) was lysogenized with the various mutant phages. To characterize the ability of the CRPs encoded by the mutant genes to function with or without cyclic nucleotides, the synthesis of 3-galactosidase, the product of the lacZ gene, was measured ( Table 2 ). The lac operon is dependent upon a functional CRP for expression (13, 26) . A strain (G698) that is crp+ but Acya cannot express ,B-galactosidase unless cAMP is added exogenously ( Table 2) . Cyclic GMP (cGMP) has very little effect on wild-type CRP. Although the amount of 3-galactosidase made by amino acid changes at positions 141 (glycine serine) and 144 (alanine -+ threonine) in the absence of Table 2 ). The abilities of the two CRP*s and the corresponding CRP*(Sup)s to function with and without cAMP or cGMP, in terms of the structure of CRP, are discussed below.
DISCUSSION
We have reported previously mutations (crp*) in the crp gene with amino acid changes within the region of the protein that is close to a hinge that connects the cAMPbinding amino-terminal domain and the DNA-binding carboxy-terminal domain. These mutations allow cAMP independence in vivo. Two of these mutant proteins have been shown in vitro, in the absence of cyclic nucleotide, to be mimicking the conformation that CRP normally assumes only in the presence of the ligand (17; Ren et al., in press). This suggests that the hinge-containing region may be one of the sites that normally undergoes structural changes by cAMP binding. To identify other regions of the protein that also participate or contribute to that cAMP-induced conformational change, we isolated mutations within the crp gene that could suppress or weaken the crp* cAMP-independent phenotype. Genetic studies such as these are expected to reveal the spectrum of changes within the protein that make up the cAMP-induced allosteric change, and any model for the allosteric change in CRP must take the following findings from our work into account.
A mutation at position 141 allows CRP to be cAMP independent. A mutation at amino acid 127 in the C a-helix removes, to some degree, the cAMP independence from a crp-141 mutation. The threonine at position 127 in each wild-type CRP subunit is thought to form a hydrogen bond via its hydroxyl group to the 6-amino group of the adenine of the cAMP (22) (Fig. 3) . The 6-amino group of the adenine also forms a hydrogen bond to amino acid serine 128 in the opposite subunit. This has been hypothesized to be one of the ways cAMP alters the conformation of CRP, by adjusting subunit-subunit alignment (22) . In the suppressor mutant crp*-141(Sup127) where the effect of the crp*-141 mutation is neutralized to some extent, when the threonine was changed to an alanine there could not be the same hydrogen bond formed between an amino acid hydroxyl and cAMP. Note that the mutant still can be activated by cAMP, indicating that if indeed an interaction occurs between the hydroxyl group of threonine 127 and cAMP in the wild-type protein, it is not an essential part of the cAMP-induced conformational change necessary for CRP activation of transcription. This indicates that the threonine at position 127 has a different role; because of the proximity of this amino acid to those in the other subunit, it is likely that threonine 127 is involved in subunit-subunit alignment. In this model, mutation at position 127 prevents proper subunitsubunit alignment. cAMP can compensate for the mutation at 127, indicating that cAMP can bypass or overcome this subunit alignment defect by additional amino acid contacts. It has already been suggested that cAMP contacts other amino acids within CRP (those at positions 72, 82 through 84, 123, and 128 [22] ).
The following results suggest that a proper alignment of the carboxy-terminal domain with respect to the aminoterminal domain within a subunit is an important part of the cAMP-induced allosteric change. The crp* mutation at position 144, crp*-144, is suppressed for cAMP independence by amino acid changes at position 169 and 171 in the E a-helix. In the wild-type protein arginine at position 169 is believed to serve as one of the positively charged sites of CRP which establish electrostatic interactions between the protein and DNA (31) . Glutamic acid at position 171 in the wild-type protein has been suggested to form a hydrogen bond with a tyrosine at position 63, in ,-sheet 5, in the cAMP-binding pocket (31a) . This hydrogen bond functions as one of the major interaction points between the cAMPbinding domain and the DNA-binding carboxy-terminal domain, other than the peptide backbone. Although the crp*-144 mutation is allowing cAMP independence, we believe that the suppressor mutant, crp*-144(Sup169,171), has lost its ability to function in the absence of cAMP because the carboxy-and amino-terminal domains of the protein are not aligned properly with respect to each other. As in the crp*-141 suppressor mutant, cAMP addition restores activity of the crp*-144 suppressor, suggesting that cAMP-mediated domain alignment can still function. cAMP is thought to make contact with amino acids in p-strands 2 and 7, which are located in the amino-terminal domain but toward the carboxy-terminal domain (22) (Fig. 1) . We propose that such contacts help the ,B-sheets shift closer to the carboxyterminal domain, helping an interaction (attraction) between the two domains. We do not yet know whether both mutations at positions 169 and 171 are necessary to suppress the crp*-144 mutation because we have not separated them yet. The effect of amino acid substitutions at positions 169 and 171 individually on CRP are now being tried by site-directed mutagenesis.
cGMP binds to wild-type CRP but does not activate it. The partially active Crp*141 and Crp*144 apparently can be activated further by cGMP as well as by cAMP. Since there are a number of contacts that cAMP makes with CRP, we propose that there are several corresponding structural changes in wild-type CRP needed for maximal activation. Some of these structural changes, on their own, bring about partial activation. In contrast, the structural changes brought about by cGMP contact to wild-type CRP do not bring about activation on their own. In our studies, the step(s) cAMP can do but cGMP cannot in the wild-type protein is obviated by the crp* mutations. In combination with the changes brought about by the crp* mutations, the cGMP-induced structural changes can make for a fully active protein. As proposed above, the suppressor 127 mutation prevents the subunits from aligning properly in the crp*-141 mutant. The crp*-141 (Supl27) mutation still responds to cGMP, indicating that changes brought about by cGMP include the alignment of subunits. Sites at positions 169 and 171, as discussed above, may define domain-domain alignment points. Since CRP* 144(Supl69,171) responds poorly to cGMP, we suggest cGMP, unlike cAMP, does not bring about proper domaindomain alignment. When cAMP binds to CRP, it binds in a pocket in the large domain and makes contact with amino acids in that region. These contacts cause changes in four regions of CRP; at least some probably occur simultaneously. Interaction with amino acids in the C a-helix causes a change in the orientation of the entire a-helix. This in turn causes a change in the orientation of the D a-helix (step 1). cAMP binding in the pocket changes the orientation of amino acids surrounding it so that interaction between the cAMP-binding domain and the DNAbinding domain can occur (step 2). cAMP allows subunit-subunit alignment (step 3). The most important change is a result of the other changes. The DNA-binding F a-helix is pushed out away from the protein (step 4,-because of interactions 1 and 2. An additional feature is that the distance between the two F a-helices of the dimer to bind into two adjacent major grooves of DNA is achieved by step 3, the subunit-subunit alignment. cyclic nucleotide analogs tested by Ebright et al. (11) with wild-type CRP should be examined with the mutants to test this prediction.
In conclusion, based on the study of the crp* and crp*(Sup) mutations described here, we believe that cAMP effects several structural changes within CRP. Our model for the cAMP-induced allosteric change is shown in Fig. 4 . cAMP binding to one or both subunits of CRP starts, either in a chain or in parallel, events through interaction with amino acids in the cAMP-binding pocket. Our studies support at least three necessary changes, not necessarily in the following order. First, cAMP binding to the C a-helix opens tip the hinge connecting the two domains by pushing the D a-helix outward with respect to the C a-helix. The D a-helix in turn pushes the F a-helix away from the body of the protein, facilitating entrance into the DNA major grooves. Second, cAMP interacts with amino acids in the ,B roll pocket and transmits a change so that the large amino domain makes an adjustment with respect to the small domain. Third, the two subunits realign by becoming closer. The major object of the cAMP-induced allosteric change may be the exposure and positioning of the F a-helices to make contacts in the two adjacent major grooves of the DNA. Physical and biochemical comparison of wild-type CRP and CRP mutant proteins will enable us to test our proposal.
